Novo Nordisk Halts AERx Development, But Not Giving Up On All Inhaled Insulin
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novo Nordisk is halting development of its Phase III AERx inhaled insulin product after determining it would not offer measurable benefit over currently available pen injection devices, the Danish firm announced Jan. 14
You may also be interested in...
Lilly Drops Inhaled Insulin With Alkermes; Will MannKind Make Giant Leap?
Lilly is the third company to drop development of inhaled insulin, citing "increasing uncertainties in the regulatory environment" and evaluation of commercial and clinical potential. Novo Nordisk also dropped its fast-acting inhaled insulin AERx after Pfizer discontinued pioneer Exubera. MannKind CEO talks up advantages of its Technosphere product, still trying to make a go of the market
Lilly Drops Inhaled Insulin With Alkermes; Will MannKind Make Giant Leap?
Lilly is the third company to drop development of inhaled insulin, citing "increasing uncertainties in the regulatory environment" and evaluation of commercial and clinical potential. Novo Nordisk also dropped its fast-acting inhaled insulin AERx after Pfizer discontinued pioneer Exubera. MannKind CEO talks up advantages of its Technosphere product, still trying to make a go of the market
Lilly/Daiichi On Track For Prasugrel NDA By Year End, Despite Mixed Results
Lilly and Daiichi Sankyo are on track to submit an NDA for their experimental antiplatelet drug prasugrel by the end of the year despite mixed study results that showed it is more effective than Plavix but with a worrisome bleeding profile.